BIO 2009 Business Forum
Date: Tuesday, May 19, 2009
Time: 9:20 a.m. - 9:35 a.m. Eastern
Location: Georgia World Congress Center, Room 316, Atlanta, Georgia
Speaker: Dr. Dennis Kim, Senior Vice President, Medical Affairs and
Communications
Eighth Annual JMP Securities Research Conference
Date: Tuesday, May 19, 2009
Time: 9:00 a.m. - 9:30 a.m. Pacific
Location: The Ritz Carlton, San Francisco
Speaker: Graham Cooper, Chief Financial Officer
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
http://www.orexigen.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index